Join Growin Stock Community!

彥臣4732.TW Overview

TW StockBiotech. & Medical
(No presentation for 4732)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

彥臣（4732）Overall Performance

彥臣（4732）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

彥臣（4732） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

彥臣（4732）Key Information

彥臣（4732）Profile

NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL Taiwan green propolis; and NBM-BMX, an oral softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei, Taiwan.

彥臣（4732）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.92
PB Ratio
1.38
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.51%
Net Margin
-7.90%
Revenue Growth (YoY)
-28.84%
Profit Growth (YoY)
-35.25%
3-Year Revenue Growth
13.01%
3-Year Profit Growth
10.45%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.92
PB Ratio
1.38
Price-to-FCF
-
Gross Margin
52.51%
Net Margin
-7.90%
Revenue Growth (YoY)
-28.84%
Profit Growth (YoY)
-35.25%
3-Year Revenue Growth
13.01%
3-Year Profit Growth
10.45%
default symbol

4732

彥臣

20.10D

0.00%

(0.00)

  • When is 4732's latest earnings report released?

    The most recent financial report for 彥臣 (4732) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4732's short-term business performance and financial health. For the latest updates on 4732's earnings releases, visit this page regularly.

  • How much cash does 4732 have?

    At the end of the period, 彥臣 (4732) held Total Cash and Cash Equivalents of 139.39M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4732 go with three margins increasing?

    In the latest report, 彥臣 (4732) did not achieve the “three margins increasing” benchmark, with a gross margin of 49.81%%, operating margin of -30.74%%, and net margin of -42.79%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4732's profit trajectory and future growth potential.